4d molecular therapeutics salary12/9/2023 ![]() ![]() 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.ĤD-310, 4D-125 and 4D-110 are the company’s product candidates in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. ![]() 4DMT is currently advancing five product candidates in clinical development: 4D-310 for Fabry disease, 4D-125 for XLRP, 4D-150 for wet AMD, 4D-710 for cystic fibrosis and 4D-110 for choroideremia. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.ĤDMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. Securities and Exchange Commission’s (“SEC”) website at Story continues 6105, or by email at Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at or by accessing the U.S. LLC, 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. Copies of the preliminary prospectus relating to the proposed offering may be obtained, when available, from: Goldman Sachs & Co. ![]() The proposed offering will be made only by means of a prospectus. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Ī registration statement relating to these securities has been filed with the SEC but has not yet become effective. LLC, SVB Leerink and Evercore ISI are acting as joint book-running managers for the proposed offering. All of the shares in the proposed offering are to be sold by 4D Molecular Therapeutics. 4D Molecular Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock offered in the proposed offering. 26, 2021 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. In the last several years, funding sources include: iBIO, corporate partners (listed above), grants from the Searle Funds of The Chicago Community Trust, US Small Business Administration, the City of Chicago and Illinois DCEO.EMERYVILLE, Calif., Oct. Today, PROPEL has strong support from the broad life sciences community encompassing the three pillars of financial support: corporate/industry private foundations and public/government. and Takeda Pharmaceuticals North America. Industry initially led the development of PROPEL through generous support from Abbott and AbbVie, Astellas Pharma US, Inc., Baxter International Inc. This has had a strong leverage effect: for each $1 awarded, PROPEL portfolio companies raised $214 in new funding. PROPEL has awarded >$1.2 million in grants and awards since 2007. Started in 2007, PROPEL helps guide the development of formation-stage and early-stage life sciences companies by providing entrepreneurs with access to specialized resources and expertise to prepare them for early-stage funding. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |